{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-24-000195","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.401177+00:00","generated_at":"2026-05-31T12:09:30.661039+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Globus Medical Q2 revenue surges 115.9% to $629.7M; GAAP net income down 45%","bullets":["Net sales $629.7M, up 115.9% as-reported; GAAP net income $31.8M, down 45% YoY.","GAAP diluted EPS $0.23; non-GAAP diluted EPS $0.75, up 20% vs $0.63 prior year.","Non-GAAP adjusted EBITDA $190.4M (30.2% of sales); operating cash flow $54.3M, FCF $26.5M.","Raised FY2024 revenue guidance to $2.47B-$2.49B; non-GAAP EPS $2.80-$2.90.","Growth driven by NuVasive acquisition, spine product volume, enabling technology sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-24-000195","json":"https://secwatch.observer/filing/0001562762-24-000195.json","markdown":"https://secwatch.observer/filing/0001562762-24-000195.md","text":"https://secwatch.observer/filing/0001562762-24-000195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000195/0001562762-24-000195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000195/gmed-20240806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:09:30.661039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}